Bletilla striata oligosaccharides improve metabolic syndrome through modulation of gut microbiota and intestinal metabolites in high fat diet-fed mice. (September 2020)

• Record Type: Journal Article
• Authors: Hu, Baifei; Ye, Cheng; Leung, Elaine Lai-Han; Zhu, Lin; Hu, Haiming; Zhang, Zhigang; Zheng, Junping; Liu, Hongtao
• Is Part Of: Pharmacological research. Volume 159(2020)
• Publication Date: 2020-09
• Subjects: BO Bletilla striata oligosaccharides -- BA bile acid -- SCFA short-chain fatty acid -- FMT fecal microbial transplantation -- HFD high fat diet -- NCD normal chow diet -- GTT glucose tolerance test -- ITT insulin tolerance test -- AUC area under curve -- HOMA-IR homeostatic model assessment for insulin resistance -- AB antibiotics -- qRT-PCR quantitative real-time PCR -- H&E hematoxylin and eosin -- Vfat visceral fat -- Efat epididymal fat -- Sfat subcutaneous fat -- TC total cholesterol -- TG total triglyceride -- HDL-C high-density lipoprotein cholesterol -- Cd11c integrin alpha-X -- Mcp-1 monocyte chemotactic protein-1 -- Pepck phosphoenolpyruvate carboxykinase -- C/ebp-α CCAAT enhancer-binding protein α -- Ppar-γ peroxisome proliferator-activated receptor-γ -- Fasn fatty acid synthase -- Dgat diacylglycerol O-acyltransferase -- Cpt-1 carnitine palmitoyltransferase 1 -- Muc3 mucin 3 -- Mmp9 matrix metalloproteinase 9 -- Mmp2 matrix metalloproteinase 2 -- Ang4 angiogenin 4 -- Fabp4 fatty acid binding protein 4 -- Gpr43 G protein-coupled receptor 43 -- Ibabp ileal bile acid binding protein -- CA cholic acid -- UDCA ursodeoxycholic acid -- TUDCA tauroursodeoxycholic acid -- T-α-MCA tauro-α-murocholic acid -- T-β-MCA tauro-β-murocholic acid -- TDCA taurodeoxycholic acid -- TCA taurocholic acid -- DCA deoxycholic acid -- 5-HT 5-hydroxytryptamine -- LPS lipopolysaccharide -- OTU operational taxonomic Unit; Glucose (PubChem CID: 107526) -- Mannose (PubChem CID: 71317182) -- Deoxycholic acid (PubChem CID: 222528) -- Cholic acid (PubChem CID: 221493) -- Taurodeoxycholic acid (PubChem CID: 2733768) -- Tryptamine (PubChem CID: 1150) -- Valeric acid (PubChem CID: 7991) -- Indole (PubChem CID: 798); Glucolipid metabolic disorder -- Gut microbiota -- Bletilla striata -- Intestinal metabolite -- Oligosaccharide -- Prebiotic; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Research -- Periodicals; Médicaments -- Recherche -- Périodiques; Pharmacologie -- Périodiques; 615.105
• DOI: 10.1016/j.phrs.2020.104942
• Languages: English
• ISSNs: 1043-6618

Abstract

Graphical abstract: Highlights: Bletilla striata oligosaccharides (BO) improved HFD-induced metabolic syndrome. BO reversed gut microbiota dysfunction that is related to metabolic syndrome. BO partly repressed the disbalance of metabolite production by intestinal bacteria. Abstract: As traditional Chinese medicine, Bletilla striata has been widely applied to clinical treatment for its unique pharmacological profiles. This study aimed to investigate the beneficial role of Bletilla striata oligosaccharides (BO) in improving the metabolic syndrome by regulation of gut microbiota and intestinal metabolites. Treatment of HFD-fed mice with BO prevented weight gain, reversed the glucose intolerance and insulin resistance, and inhibited adipocyte hypertrophy. BO-treated mice also suppressed chronic inflammation and protected intestinal barrier from damage. These effects were linked to the reversal of gut microbiota dysbiosis, which contributed to the homeostasis of intestinal metabolites including bile acids, short-chain fatty acids and tryptophan catabolites. The depletion and reconstitution of intestinal flora from BO- or HFD-treated mice confirmed the significance of gut microbiota in regulation of HFD-induced metabolic disorders. We demonstrated for the first time that BO improved metabolic syndrome through the regulation of gut microbiota and intestinal metabolites. The modulation initiated by BO represents a promising strategy for treatment of obesity and related metabolic diseases.